Natera Submits Signatera to Japan PMDA for MIBC Approval
AUSTIN, Texas, August 5, 2026 Natera, Inc. has submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)...
atezolizumab
Advertisement
Treos Bio Reports PolyPEPI1018 Immune Remodeling Data
LONDON, Boston & Budapest, July 2, 2026 Treos Bio announced new translational findings from its Phase Ib/II OBERTO-301 clinical...
Jazz Reports Phase 3 LAGOON Results for Zepzelca in SCLC
DUBLIN, Ireland, June 12, 2026 Jazz Pharmaceuticals has announced topline results from the Phase 3 LAGOON trial evaluating Zepzelca®...
FDA Grants Priority Review to Genentech’s Tecentriq for Early Colon Cancer
SOUTH SAN FRANCISCO, Calif., June 10, 2026 Genentech, a member of the Roche Group, announced that the U.S. Food...
Rznomics RZ-001 Shows Strong HCC Clinical Data AACR
SAN DIEGO, Calif., April 19, 2026 Rznomics Inc. announced encouraging interim clinical results from its ongoing study of RZ-001,...
Advertisement
